Dru Medicati Mechanis Pharmacok Contraindi Side Clinicall Nursing

g on and m of inetics/ cations Effects y consider

Directio Action Pharmacod importa ations
n ynamics nt drug and
foo teaching
drug plan
interact
ions
Levodop Carbidopa Hypersensi CNS:
Gen a is extends the tivity involunt MAOI Disturbe
eric Carbido converte half-life of ary increas d
Na pa- d to levodopa Narrow- movem ed thought
me: levodop dopamin as well as angle ents, therape process
a e in the lengthens glaucoma anxiety, utic related
Central its blood dizzines effects to CNS
Bra Nervous plasma Allergy to s, and effects
nd Sinemet System level. carbidopa/l hallucin risk of
Na (CNS), evodopa or ations, hyperte Constipa
me: where it any other memory nsive tion
serves as When ingredients loss, crisis. related
Drug
carbidopa of Sinemet psychiat MAOI to
classific neurotran
smitter. and ric should dopamin
ation: People
Carbidop levodopa problem be ergic
a, a are who taken s. stoppe effects
Dopami decarbox administere a d 14
ylase d together, nonselectiv EENT: days Risk for
nergic
inhibitor, 75% less of e MAO blurred before urinary
Agents
prevents levodopa inhibitor vision beginni retention
Antichol periphera has the within past and ng related
inergic l same effect 2 weeks. mydrias dopami to
Agents destructio if levodopa is. nergic dopamin
n of was Precautio therapy ergic
Others levodopa. administere n: GI: effects
Consequ d alone. nausea, Vitamin
ently, Heart vomitin B6 Risk for
more problems, g, phenyt injury
levodopa Route: oral such as anorexi oin: related
is Onset: heart a, dry decrea to CNS
delivered Varies attack or mouth, sed effects
to CNS Peak: 0.5- high or low and levodo and
using a 2hrs. blood hepatot pa orthostati
smaller Duration: 5 pressure. oxicity. efficacy c
dose hrs. hypotens
when Ulcers in Derma: Over ion.
used with T1/2: 1- the Melano the
carbidop 3hrs. stomach ma counter Impleme
Metabolism vitamin: ntation:
a. : Liver Glaucoma Hemat: decrea
Excretion: hemolyt sed Decreas
Kidney Psychotic ic dopami e dose of
Indication (urine). disorders anemia nergic the drug
s and effectiv as
Dopamin Pharmacod Allergic leukope eness ordered
ergic are ynamics: reaction nia. if therapy
indicated has been
for the In patients Pregnancy Misc: interrupt
relief of with Darkeni ed to
the signs Parkinson’s Breastfeed ng of prevent
and disease, ing urine or systemic
symptom the oral sweat. dopamin
s of dosing of ergic
idiopathic extended- Respira effects.
Parkinso release tory:
n’s carbidopa- bizarre Evaluate
disease. levodopa breathin disease
achieves g progress
Levodop an onset patterns and
a is the peak of signs
drug of levodopa and
choice plasma symptom
and acts concentrati s
as a on within 1 periodica
replacem hour and lly for
ent maintains referenc
therapy them for 4- e of
6 hours. disease
Amantadi progress
ne is an and drug
antiviral response
drug that
increases Give
release drug with
of meals to
dopamin alleviate
e. GI
irritation
Apomorp if present
hine
directly Monitor
binds bowel
with function
postsyna and
ptic institute
dopamin bowel
e program
receptors if
constipat
ion is
severe.

Have
patient
void
before
taking
the
drugs to
decrease
risk of
urinary
retention

Monitor
laborator
y results
such as
renal
and liver
function,
CBC to
detect
early
signs of
dysfuncti
on.

Provide
comfort
measure
s to help
tolerate
drug
effects.

Provide
safety
measure
s such
as
adequat
e
lighting,
raised
side
rails, and
etc. to
prevent
injuries

Educate
client on
drug
therapy
to
promote
understa
nding
and
complian
ce.